Early Cardiac Rehabilitation Improved Prognosis in Patients with Heart Failure Following Acute Myocardial Infarction

He Cai  
Jilin University

Pengyu Cao (caopy1979@outlook.com)  
The Cardiovascular Center, The First Hospital of Jilin University  
https://orcid.org/0000-0003-0560-5159

Wanqing Sun  
Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital

Xinying Zhang  
jilin university

Rongyu Li  
Jilin university

Wangshu Shao  
Jilin university

Lin Wang  
Jilin university

Lin Zou  
Jilin university

Yang Zheng  
Jilin university

Research article

Keywords: Cardiac rehabilitation, Cardio-respiratory fitness, Cardio-pulmonary exercise, Heart failure, Myocardial infarction, Percutaneous coronary intervention

DOI: https://doi.org/10.21203/rs.3.rs-36808/v1

License: ☑️ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Cardiac rehabilitation (CR) has been shown to improve exercise intolerance and QoL, and minimize re-hospitalizations in patients with congestive heart failure (CHF). However, studies on early CR in patients with acute myocardial infarction (AMI) who developed CHF following percutaneous coronary intervention (PCI) are rare. The purpose of this study is to evaluate the effectiveness of early CR on patients with CHF after AMI following PCI.

**Methods:** Two hundred thirty-seven patients who developed heart failure after AMI following PCI were enrolled. Patients were divided into heart failure with reduced ejection fraction (HFrEF) group and heart failure with mid-range ejection fraction (HFmrEF) group. Of which, 78 patients who accepted a two-week CR were further divided into two subgroups based on major adverse cardiovascular events (MACE). Key cardio-pulmonary exercise testing (CPX) variables that may affect the prognosis were identified through the comparison of the cardio-respiratory fitness (CRF).

**Results:** Early CR significantly reduced cardiac death in patients with HFrEF, and reduced re-hospitalization in patients with HFmrEF after AMI (P <0.01). Serum potassium and CR ratio were independent risk factors for MACE in patients with both HFrEF and HFmrEF after AMI. In the CR group who developed MACE, there were more diabetics (P=0.035), with higher serum potassium (P=0.043), and lower P_{ET}CO_{2} at VT (P=0.016). P_{ET}CO_{2} at VT was an independent risk factor for re-hospitalization. The incidence of re-hospitalization was significantly lower when the P_{ET}CO_{2} at VT was greater than 33.5mmHg (P=0.03).

**Conclusions:** Early CR reduced the incidence of MACE in patients with heart failure after AMI following PCI. The P_{ET}CO_{2} at VT is an independent risk factor for re-hospitalization, and could be used as a key evaluating hallmark for early CR in patients who developed heart failure after AMI.

Background

Congestive heart failure (CHF) is a major cause of mortality and morbidity and the end pathophysiological condition of many cardiovascular diseases [1]. One of the leading causes of CHF is myocardial infarction. Percutaneous coronary intervention (PCI) significantly decreased the mortality in patients with acute myocardial infarction (AMI) [2]. However, CHF continues to develop in some patients before or soon after PCI.

Exercise intolerance, represented as decreased capacity to perform physical activities with symptoms of severe fatigue and/or dyspnea, is a characteristic of CHF and associated with increased mortality and reduced quality of life (QoL) [3]. The pathophysiological mechanisms of exercise intolerance in CHF are multifactorial, involving impaired cardiac and pulmonary reserve as well as decreased respiratory and peripheral skeletal muscle function [4]. In addition to conventional treatment, many researchers have shown that cardiac rehabilitation (CR) can improve exercise intolerance and QoL, and minimize re-hospitalizations in patients with CHF [5,6]. However, studies on early CR in patients who developed CHF soon after AMI following PCI are scarce. A pilot study done by Houchen L et al. indicated that early CR could significantly reduce depression, enhance exercise tolerance and decrease CHF-associated hospital admission [7]. However, the study population was small and no control group was presented for comparison. In view of this, this study evaluated patients with CHF after AMI following PCI with
and without CR, and compared biochemical parameters and cardio-respiratory fitness (CRF), as well as long-term prognosis at 4 years follow-up.

**Methods**

**Patient population:**

From January 2015 to January 2016, patients admitted for acute ST elevation myocardial infarction with CHF following PCI were identified in the Department of Cardiology at the First Hospital of Jilin University. The study protocol was approved by the Institutional Review Board of the hospital.

Patients’ baseline characteristics and biochemical parameters were collected from medical records. According to the 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [8], patients were divided into heart failure with reduced ejection fraction (HFrEF) group and heart failure with mid-range ejection fraction (HFmrEF) group. In each group, patients were further divided into CR and non-CR subgroups. CR consisted 2 weeks exercise including 3 supervised regular exercise sessions per week on a bicycle [9] and 4 supervised electrical stimulation sessions per week for no regular exercise day [10]. Regular exercise session lasted for 20 minutes including warm-up and cool-down, and included three 3-minute intervals aiming at Borg 11–13 by subjective sensation separated by 2-minute recovery periods of 0 watt intensity [9]. Electrical stimulation was performed 30 min/day, 4 days per week, using a dual-channel battery-powered stimulator Elpha-II 3000 (DANMETER® A/S, Odense, Denmark). The stimulator delivered a biphasic current of 25 Hz frequency. The electrical current characteristics were set up as follows: “on–off” mode stimulus (3 s stimulation, 6 s rest), pulse width 300us, rise and fall time 1 s. The intensity of the stimulation was adjusted to produce a visible muscle contraction but not too strong to make the patients uncomfortable [10]. Adhesive electrodes were placed on both legs over the upper and lower aspects of gastrocnemius muscles, and over the upper-lateral and lower-medial portions of the quadriceps muscles. After the 2 weeks CR, patients were advised to continue individualized exercise at home for 3–4 sessions per week. Individualized exercise prescription was created based on each patient’s CRF from cardio-pulmonary exercise testing (CPX) before discharge [11]. Patients who accepted the 2-weeks CR were subsequently reassigned into two subgroups based on the major adverse cardiac events (MACE), namely the MACE group and the non-MACE group. The parameters of CRF between the two subgroups were compared, and the main CPX variables that may predict the prognosis of patients with CHF were identified.

**Quantification of cardio-respiratory fitness**

CPX, which is a widely accepted evaluation tool in both the United States and Europe [12, 13], was used for the assessment of CRF. The measurement of ventilatory gas exchange was used to predict prognosis of death and re-hospitalization [13–15]. In CR patients, the oxygen consumption (\(\text{VO}_2\)), carbon dioxide production (\(\text{VCO}_2\)), minute ventilation (VE), partial pressure of end-tidal carbon dioxide (\(\text{PETCO}_2\)), respiratory exchange ratio (RER) and other key CPX variables were measured with submaximal graded exercise test using Cardio-respiratory instrumentation Medisoft (Made in Belgium, Model:E100000011000001 N:130619–05-1470, ) after 2-week CR. The exercise load was determined via a cycle ergometer work rate. The progressive load was 10 watts per minute during the graded exercise test. The exercise test was terminated if the patient developed any of the following subjective or objective conditions: abnormal hemodynamic or electrocardiographic exercise response, or other causes such as dyspnea, angina or lower extremity muscle fatigue.
Clinical follow-up

Follow-up data was acquired through hospital records and telephone interviews which were conducted every 3 months from discharge until cardiac death or July 2019, whichever came first. MACE including cardiac death and re-hospitalization were documented. Patients with cardiac death who lost telephone interviews were identified from the population registry bureau. The average duration of follow-up was 4 years.

Statistical analysis

Continuous variables were expressed as means ± standard deviation, and non-normally distributed variables were presented as medians (interquartile range). Categorical variables were expressed as numbers and percentages. Variable parameters between the groups were compared with means of one-way analysis of variance, or Mann-Whitney U test for continuous variables and chi-square test for dichotomous variables, as appropriate. In all analyses, a two-tailed \( p < 0.05 \) was considered as statistical significance.

Cox multivariate regression analysis, in which test indices and variables showing \( p < 0.05 \) in the univariate analysis were included, was used to determinate independent risk factors for MACE. A receiver operating characteristic (ROC) curve was used to predict the prognosis for MACE. All statistical analysis data were performed using the SPSS 19 software (IBM Corp., Armonk, NY, USA).

Results

A total of 274 patients of AMI with CHF following PCI were identified, after excluding 21 patients who were lost to follow-up and 16 patients who were not able to participate cardiopulmonary exercise testing (CPX) (Table 1), 237 patients were included in the final analyses. Of which, 55 patients had HFrEF (n = 22 in CR and n = 33 in non-CR group) and 182 had HFmrEF (n = 56 in CR and n = 126 in non-CR group).

Table 1

| Reason of not administering exercise prescriptions | Number of patients |
|--------------------------------------------------|--------------------|
| Multiple organ failure                           | 2                  |
| Uremia                                           | 2                  |
| Ankylosing spondylitis                           | 6                  |
| Diabetic ketosis                                 | 1                  |
| Diabetic foot                                    | 1                  |
| Systemic lupus erythematosus                     | 1                  |
| Tumours                                          | 1                  |
| After aortic stent implantation                  | 1                  |
| Left ventricular apical thrombosis               | 1                  |
| Total                                            | 16                 |
In HFrEF group, there were no significant differences in baseline characteristics between CR and non-CR groups except that the non-CR group patients were older with fewer smokers. In HFmrEF group, there were more male patients in non-CR group otherwise there were no significant differences in baseline characteristics between CR and non-CR groups (Table 2).
Table 2
Comparison of MACE (4 years) in two groups.

|                  | HFrEF group (n = 55) | HFmrEF group (n = 182) |
|------------------|----------------------|------------------------|
|                  | CR (n = 22)          | NCR (n = 33)           | P      | CR (n = 56) | NCR (n = 126) | P      |
| Sex, male (%)    | 17(77.3%)            | 26(78.8%)              | 1.000  | 36(64.3%)   | 99(78.6%)     | 0.046  |
| Age (years)      | 57.09 ± 9.17         | 64.94 ± 7.81           | 0.001  | 58.84 ± 10.37 | 59.63 ± 12.47 | 0.677  |
| History of hypertension, n (%) | 13(59.1%) | 15(45.5%)              | 0.412  | 29(51.8%)   | 60(47.6%)     | 0.633  |
| History of diabetes, n (%) | 6(27.3%)   | 12(36.4%)              | 0.565  | 14(25%)     | 36(28.6%)     | 0.720  |
| Smoking history, n (%) | 16(72.7%) | 14(42.4%)              | 0.032  | 28(50%)     | 79(62.7%)     | 0.142  |
| History of stroke, n (%) | 2(9.1%)   | 2(6.1%)                | 1.000  | 1(1.8%)     | 9(7.1%)       | 0.285  |
| WBC (10⁹/L), median (IQR) | 9.13 ± 3.22 | 10.36 ± 3.73           | 0.212  | 9.88        | (7.70,12.89)  | 0.913  |
| Platelet (10⁹/L), median (IQR) | 217.45 ± 67.00 | 197.42 ± 75.13         | 0.317  | 228.5       | (186,271.75)  | 0.128  |
| HGB (g/l)        | 139 ± 22.31          | 133.39 ± 20.31         | 0.339  | 141.68 ± 17.316 | 142.24 ± 18.165 | 0.846  |
| Blood potassium (mmol/l) | 4.06 ± 0.40      | 4.22 ± 0.53            | 0.229  | 3.92(3.66,4.14) | 4.03(3.77,4.28) | 0.123  |
| Urea nitrogen (mmol/l), median (IQR) | 6.19 ± 1.57       | 5.76 ± 2.30            | 0.451  | 5.27(4.20,6.27) | 5.57(4.80,6.91) | 0.136  |
| Creatinine (umol/L), median (IQR) | 76.70          | (64.25,92.85)          | 0.904  | 63.80       | (56.53,82.80)  | 0.541  |
| AST (U/L), median (IQR) | 108.3            | (22.05,353.72)         | 0.327  | 71.65       | (34.43,198.98)  | 0.151  |
| ALT (U/L), median (IQR) | 44.05            | (25.33,76.45)          | 0.624  | 45.15       | (24.20,67.63)  | 0.536  |

HFrEF: Heart failure with reduced ejection fraction, HFmrEF: Heart failure with mid-range ejection fraction, CR: Cardiac rehabilitation, NCR: Non cardiac rehabilitation, WBC: White blood cell, HGB: Hemoglobin, AST: Glutamic pyruvic transaminase, ALT: Glutamic pyruvic aminotransferase, HDL-C: High density lipoprotein cholesterol, non- HDL-C: non-High density lipoprotein cholesterol, TC: total cholesterol, FBS: Fasting blood sugar, EDLV: End diastolic diameter of left ventricle, EF: Ejection fraction, LM: The left main coronary artery, LAD: Left anterior descending branch, LCX: Left circumflex branch, RCA: Right coronary artery, MACE: major cardiac events, IQR: Interquartile range.
|                      | HFrEF group(n = 55) | HFmrEF group(n = 182) |
|----------------------|---------------------|----------------------|
| HDL-C (mmol/l)       | 1.09 ± 0.23         | 1.16 ± 0.33          |
|                      | 0.380               | 1.19(1.00,1.38)      |
|                      | 1.21(1.00,1.52)      | 0.306               |
| non-HDL-C (mmol/l)   | 3.58 ± 0.95         | 3.46 ± 1.28          |
|                      | 0.707               | 3.60 ± 0.93          |
|                      | 3.48 ± 1.07         | 0.467               |
| TC (mmol/L), median (IQR) | 1.46(1.07,2.03)   | 1.31(0.93,2.18)      |
|                      | 0.525               | 1.33(1.00,2.02)      |
|                      | 1.40(1.02,2.07)      | 0.832               |
| FBS (mmol/L), median (IQR) | 6.14(5.51,7.39)   | 7.08(5.84,11.04)     |
|                      | 0.071               | 6.60(4.93,8.37)      |
|                      | 6.59(5.37,9.50)      | 0.350               |
| EDLV (mm)            | 58.09 ± 5.52        | 54.88 ± 6.13         |
|                      | 0.053               | 52.04 ± 5.30         |
|                      | 51.19 ± 5.02         | 0.304               |
| EF (%), median (IQR) | 34(31,37)           | 35(30,38)            |
|                      | 0.938               | 46(42,48)            |
|                      | 46(44,49)            | 0.050               |
| Target lesion location |                    |                     |
| LAD, n (%)           | 10(45.5%)           | 17(51.5%)            |
|                      | 0.790               | 41(73.2%)            |
|                      | 88(69.8%)            | 0.730               |
| LCX, n (%)           | 2(9.1%)             | 3(9.1%)              |
|                      | 1.000               | 2(3.6%)              |
|                      | 6(4.8%)              | 1.000               |
| RCA, n (%)           | 10(45.5%)           | 13(39.4%)            |
|                      | 0.782               | 13(23.2%)            |
|                      | 32(25.4%)            | 0.853               |
| KILLIP class         |                      |                     |
| I, n (%)             | 0(0.0%)             | 0(0.0%)              |
|                      | -                   | 0(0.0%)              |
|                      | 0(0.0%)              |                     |
| II, n (%)            | 7(31.8%)            | 12(36.4%)            |
|                      | 0.780               | 31(55.4%)            |
|                      | 73(57.9%)            | 0.750               |
| III, n (%)           | 12(54.5%)           | 10(30.3%)            |
|                      | 0.100               | 13(23.2%)            |
|                      | 28(22.2%)            | 1.000               |
| IV, n (%)            | 3(13.6%)            | 11(33.3%)            |
|                      | 0.130               | 12(21.4%)            |
|                      | 25(19.8%)            | 0.840               |
| Cardiogenic death, n (%) | 0(0.0%)        | 11(33.3%)            |
|                      | **0.002**            | 0(0.0%)              |
|                      |                     | 9(7.1%)              |
|                      |                     | 0.059               |

HFrEF: Heart failure with reduced ejection fraction, HFmrEF: Heart failure with mid-range ejection fraction, CR: Cardiac rehabilitation, NCR: Non cardiac rehabilitation, WBC: White blood cell, HGB: Hemoglobin, AST: Glutamic pyruvic transaminase, ALT: Glutamic pyruvic aminotransferase, HDL-C: High density lipoprotein cholesterol, non- HDL-C: non-High density lipoprotein cholesterol, TC: total cholesterol, FBS: Fasting blood sugar, EDLV: End diastolic diameter of left ventricle, EF: Ejection fraction, LM: The left main coronary artery, LAD: Left anterior descending branch, LCX: Left circumflex branch, RCA: Right coronary artery, MACE: major cardiac events, IQR: Interquartile range.
Incidence of major cardiovascular events

In the HFrEF group, non-CR patients had higher MACE rate (P = 0.002) due to higher incidence of cardiac death (P = 0.002) as compared to CR patients (Table 2, Fig. 1). In the HFmrEF group, non-CR patients had higher MACE rate (P < 0.001) due to higher incidence of heart failure (HF) re-hospitalization (P = 0.008) as compared to CR patients (Table 2, Fig. 1).

In HFrEF group, patients who developed MACE had higher serum potassium level (P = 0.001), lower left ventricular end diastolic diameter (P = 0.018) and CR ratio (P = 0.002) compared to patients who did not have MACE (Table 3). Serum potassium (OR = 2.793, 95%CI: 1.207–6.465, P = 0.016) and CR ratio (OR = 0.298, 95%CI: 0.099–0.902, P = 0.032) were independent risk factors for MACE of HFrEF patients, as shown in Table 5. In HFmrEF group, patients who developed MACE tended to be female (P = 0.013), older (P < 0.001), with history of stroke (P = 0.035), with lower hemoglobin (P = 0.012), higher serum potassium (P = 0.009), and lower the CR ratio (P < 0.001) (Table 4). Sex (OR = 2.411, 95%CI: 1.150–5.054, P = 0.020), age (OR = 1.039, 95%CI: 1.008–1.071, P = 0.014), history of stroke (OR = 3.628, 95%CI: 1.288–10.219, P = 0.015), serum potassium (OR = 3.054, 95%CI: 1.739–5.362, P < 0.001), CR ratio (OR = 0.115, 95%CI: 0.028–0.482, P = 0.003) were independent risk factors for MACE of HFmrEF patients, as shown in Table 6.
Table 3
Comparison of baseline data in the HFrEF group

|                                | Non-MACE(n = 31) | MACE(n = 24) | P     |
|--------------------------------|------------------|--------------|-------|
| Sex, male (%)                 | 26(83.9%)        | 17(70.8%)    | 0.328 |
| Age (years)                   | 59.90 ± 8.24     | 64.25 ± 9.87 | 0.081 |
| History of hypertension, n (%)| 18(58.1%)        | 10(41.7%)    | 0.282 |
| History of diabetes, n (%)    | 7(22.6%)         | 11(45.8%)    | 0.087 |
| Smoking history, n (%)        | 18(58.1%)        | 12(50.0%)    | 0.594 |
| History of stroke, n (%)      | 4(12.9%)         | 0(0.0%)      | 0.123 |
| WBC (10⁹/L)                   | 9.43 ± 3.16      | 10.43 ± 4.00 | 0.306 |
| Platelet (10⁹/L)              | 209.97 ± 69.14   | 199.58 ± 76.70 | 0.601 |
| HGB (g/l)                     | 140.39 ± 19.80   | 129.50 ± 21.57 | 0.057 |
| Blood potassium(mmol/l)       | 3.97 ± 0.33      | 4.40 ± 0.54  | 0.001 |
| Urea nitrogen(mmol/l)         | 6.26 ± 1.82      | 5.53 ± 2.33  | 0.196 |
| Creatinine (umol/L), median (IQR) | 80.90(66.70,92.90) | 73.30(61.93,95.83) | 0.524 |
| AST (U/L), median (IQR)       | 89.70(25.20,363.70) | 144.75(28.43,380.45) | 0.333 |
| ALT (U/L), median (IQR)       | 49.20(26.10,70.10) | 55.15(22.33,126.3) | 0.297 |
| HDL-C (mmol/l)                | 1.13 ± 0.23      | 1.14 ± 0.36  | 0.936 |
| non-HDL-C (mmol/l), median (IQR) | 3.31(2.93,4.79)  | 3.29(2.36,3.88) | 0.135 |
| TC (mmol/L), median (IQR)     | 1.57(1.07,2.14)  | 1.23(0.82,2.00) | 0.133 |
| FBS (mmol/L), median (IQR)    | 6.14(5.43,8.74)  | 7.19(6.00,10.41) | 0.058 |
| EDLV (mm)                     | 57.84 ± 5.67     | 54.00 ± 5.96 | 0.018 |
| EF (%), median (IQR)          | 33.48 ± 4.96     | 33.58 ± 4.71 | 0.940 |
| CR, n (%)                     | 18(58.1%)        | 4(16.7%)     | 0.002 |

WBC: white blood cell, HGB: Hemoglobin, AST: Glutamic pyruvic transaminase, ALT: Glutamic pyruvic aminotransferase, HDL-C: High density lipoprotein cholesterol, non- HDL-C: non-High density lipoprotein cholesterol, TC: Total cholesterol, FBS: Fasting blood sugar, EDLV: End diastolic diameter of left ventricle, EF: Ejection fraction, CR: cardiac rehabilitation, MACE: major cardiac events, IQR: Interquartile range.
|                                                                 | Non-MACE(n = 144) | MACE(n = 38) | P        |
|-----------------------------------------------------------------|-------------------|--------------|----------|
| Sex, male (%)                                                   | 113 (78.5%)       | 22 (57.9%)   | 0.013    |
| Age (years)                                                    | 57.69 ± 11.64     | 65.84 ± 10.41 | <0.001   |
| History of hypertension, n (%)                                  | 70 (48.6%)        | 19 (50%)     | 1.000    |
| History of diabetes, n (%)                                     | 41 (28.5%)        | 9 (23.7%)    | 0.684    |
| Smoking history, n (%)                                         | 90 (62.5%)        | 17 (44.7%)   | 0.063    |
| History of stroke, n (%)                                        | 5 (3.5%)          | 5 (13.2%)    | 0.035    |
| WBC (10⁹/L)                                                    | 10.53 ± 3.44      | 9.73 ± 2.64  | 0.184    |
| Platelet (10⁹/L)                                               | 218 (181.75,250)  | 231.5(186.5,262.25) | 0.365    |
| HGB (g/l)                                                      | 143.76 ± 17.38    | 135.63 ± 18.44 | 0.012    |
| Blood potassium (mmol/l), median (IQR)                         | 3.98(3.66,4.17)   | 4.12(3.89,4.41) | 0.009    |
| Urea nitrogen (mmol/l), median (IQR)                           | 5.52(4.65,6.74)   | 5.57(5.03,6.38) | 0.942    |
| Creatinine (umol/L), median (IQR)                              | 67.85(57.20,79.40) | 74.40(58.40,85.88) | 0.213    |
| AST (U/L), median (IQR)                                        | 73.45(37.50,212.43) | 101.40(47.58,243.68) | 0.279    |
| ALT (U/L), median (IQR)                                        | 44.50(25.95,68.13) | 52.95(31.28,74.47) | 0.158    |
| HDL-C (mmol/l)                                                 | 1.24 ± 0.34       | 1.27 ± 0.38  | 0.551    |
| non-HDL-C(mmol/l), median (IQR)                                | 3.48(2.95,4.08)   | 3.43(2.66,4.30) | 0.783    |
| TC (mmol/L), median (IQR)                                      | 1.40(1.04,2.00)   | 1.36(0.97,2.49) | 0.753    |
| FBS (mmol/L), median (IQR)                                     | 6.54(5.21,9.18)   | 6.62(5.88,9.61) | 0.162    |
| EDLV (mm)                                                      | 51.52 ± 5.10      | 51.18 ± 5.19  | 0.719    |
| EF (%), median (IQR)                                           | 46(44,49)         | 46(42,47)    | 0.095    |
| CR, n (%)                                                      | 54(37.5%)         | 2(5.3%)      | <0.001   |

WBC: white blood cell, HGB: Hemoglobin, AST: Glutamic pyruvic transaminase, ALT: Glutamic pyruvic aminotransferase, HDL-C: High density lipoprotein cholesterol, non-HDL-C: non-High density lipoprotein cholesterol, TC: Total cholesterol, FBS: Fasting blood sugar, EDLV: End diastolic diameter of left ventricle, EF: Ejection fraction, CR: cardiac rehabilitation, MACE: major cardiac events, IQR: Interquartile range.
Table 5
Analysis of risk factors of MACE in patients with HFrEF (Cox multivariate regression analysis)

|                      | OR   | 95% CI      | P   |
|----------------------|------|-------------|-----|
| EDLV (mm)            | 0.931| 0.866–1.001 | 0.054|
| Blood potassium (mmol/l) | 2.793| 1.207–6.465 | 0.016|
| CR                   | 0.298| 0.099–0.902 | 0.032|

EDLV: End diastolic diameter of left ventricle, CR: Cardiac rehabilitation.

Table 6
Analysis of risk factors of MACE in patients with HFmrEF (Cox multivariate regression analysis)

|                      | OR   | 95% CI      | P   |
|----------------------|------|-------------|-----|
| Sex, male (%)        | 2.411| 1.150–5.054 | 0.020|
| Age (years)          | 1.039| 1.008–1.071 | 0.014|
| HGB (g/l)            | 0.987| 0.966–1.009 | 0.240|
| Blood potassium (mmol/l) | 3.054| 1.739–5.362 | <0.001|
| History of stroke (%)| 3.628| 1.288–10.219| 0.015|
| CR                   | 0.115| 0.028–0.482 | 0.003|

HGB: Hemoglobin, CR: Cardiac rehabilitation.

The main CPX variables for prognosis prediction

The 78 patients who accepted the 2-weeks CR were subsequently reassigned into two subgroups based on the MACEs, namely the MACE group (n = 6) and the non-MACE group (n = 72) (Table 7).
|                          | Non-MACE (n = 72) | MACE (n = 6) | P     |
|--------------------------|-------------------|--------------|-------|
| Sex, male (%)            | 49 (68.1%)        | 4 (66.7%)    | 1.000 |
| Age (years)              | 58.93 ± 9.52      | 52.33 ± 6.95 | 0.103 |
| History of hypertension, n (%) | 39 (54.2%)  | 3 (50.0%)    | 1.000 |
| History of diabetes, n (%) | 16 (22.2%)      | 4 (66.7%)    | 0.035 |
| Smoking history, n (%)   | 40 (55.6%)        | 4 (66.7%)    | 0.691 |
| History of stroke, n (%) | 3 (4.2%)          | 0 (0.0%)     | 1.000 |
| WBC (10⁹/L), median (IQR) | 9.55(7.55,12.35) | 7.28(5.34,11.55) | 0.195 |
| Platelet (10⁹/L)         | 230.4 ± 64.39     | 240.33 ± 73.55 | 0.721 |
| HGB (g/l)                | 140.77 ± 18.53    | 134.00 ± 21.68 | 0.400 |
| Blood potassium (mmol/l), median (IQR) | 3.96(3.66,4.17) | 4.31(3.96,4.63) | 0.043 |
| Urea nitrogen (mmol/l)   | 5.70 ± 1.57       | 5.30 ± 1.11  | 0.546 |
| Creatinine (umol/L), median (IQR) | 71.05(57.90,88.80) | 73.80(62.03,129.95) | 0.579 |
| AST (U/L), median (IQR)  | 70.35(29.43,203.52) | 70.50(33.60,167.83) | 0.751 |
| ALT (U/L), median (IQR)  | 41.40(23.30,65.30) | 66.25(35.38,102.98) | 0.111 |
| HDL-C (mmol/l)           | 1.17 ± 0.25       | 0.99 ± 0.18  | 0.106 |
| non-HDL-C (mmol/l), median (IQR) | 3.48(3.01,4.18) | 3.51(3.01,4.39) | 1.000 |
| TC (mmol/L), median (IQR) | 1.40(1.08,2.00)  | 1.67(1.05,3.63) | 0.559 |
| FBS (mmol/L), median (IQR) | 6.47(5.16,8.25) | 6.20(5.26,7.77) | 0.882 |
| EDLV (mm)                | 53.66 ± 6.22      | 55.33 ± 5.28 | 0.526 |
| EF (%), median (IQR)     | 42 (39.46)        | 38.5 (31.5,46.0) | 0.179 |
| HFrEF, n (%)             | 51 (70.8%)        | 4 (66.7%)    | 1.000 |

WBC: White blood cell, HGB: Hemoglobin, AST: Glutamic pyruvic transaminase, ALT: Glutamic pyruvic aminotransferase, HDL-C: High density lipoprotein cholesterol, non- HDL-C: non-High density lipoprotein cholesterol, TC: total cholesterol, FBS: Fasting blood sugar, EDLV: End diastolic diameter of left ventricle, EF: Ejection fraction, HFrEF: Heart failure with reduced ejection fraction, LM: The left main coronary artery, LAD: Left anterior descending branch, LCX: Left circumflex branch, RCA: Right coronary artery, R-HR: Rest heart rate, E-HR: Exercise Heart Rate, E-VE: Exercise Minute ventilation, Δ VE: Margin of Minute ventilation, VE/MVV%: The ratio of minute ventilation to the maximum expected value, VO₂ at VT: Oxygen consumption per kilogram of weight per minute at anaerobic threshold, E-VO₂: Exercise Carbon dioxide production, Δ VCO₂: Margin of Minute ventilation Carbon dioxide production, VE/VO₂ slope: Minute ventilation/Carbon dioxide production, R-P<sub>ET</sub>CO₂: Rest Partial pressure of end-tidal carbon dioxide, P<sub>ET</sub>CO₂ at VT: Partial pressure of end-tidal carbon dioxide at anaerobic threshold, Δ P<sub>ET</sub>CO₂: Margin of Partial pressure of end-tidal carbon dioxide, MACE: major cardiac events, IQR: Interquartile range.
| KILLIP class | Non-MACE(n = 72) | MACE(n = 6) | P     |
|-------------|------------------|------------|-------|
| I, n (%)    | 0(0.0%)          | 0(0.0%)    | -     |
| II, n (%)   | 34(47.2%)        | 4(66.7%)   | 0.425 |
| III, n (%)  | 23(31.9%)        | 2(33.3%)   | 1.000 |
| IV, n (%)   | 15(20.8%)        | 0(0.0%)    | 0.590 |

| Target lesion location | Non-MACE(n = 72) | MACE(n = 6) | P     |
|------------------------|------------------|------------|-------|
| LAD, n (%)             | 49(68.1%)        | 2(33.3%)   | 0.174 |
| LCX, n (%)             | 3(4.2%)          | 1(16.7%)   | 0.279 |
| RCA, n (%)             | 20(27.8%)        | 3(50.0%)   | 0.353 |

| Rehospitalization, n (%) | Non-MACE(n = 72) | MACE(n = 6) | P     |
|--------------------------|------------------|------------|-------|
|                         | 0(0.0%)          | 6(100.0%)  | <0.001|

| Myocardial infarction, n (%) | Non-MACE(n = 72) | MACE(n = 6) | P     |
|-----------------------------|------------------|------------|-------|
|                            | 0(0.0%)          | 2(33.3%)   | 0.005 |

| Heart failure, n (%) | Non-MACE(n = 72) | MACE(n = 6) | P     |
|----------------------|------------------|------------|-------|
|                      | 0(0.0%)          | 4(66.7%)   | <0.001|

| Stroke, n (%) | Non-MACE(n = 72) | MACE(n = 6) | P     |
|--------------|------------------|------------|-------|
|              | 0(0.0%)          | 0(0.0%)    | -     |

| R-HR (bpm), median (IQR) | Non-MACE(n = 72) | MACE(n = 6) | P     |
|--------------------------|------------------|------------|-------|
|                          | 72(67,81)        | 79(56,90.5)| 0.751 |

| E-HR (bpm), median (IQR) | Non-MACE(n = 72) | MACE(n = 6) | P     |
|--------------------------|------------------|------------|-------|
|                          | 95(87,109)       | 105.5(89.75,118.25) | 0.317 |

WBC: White blood cell, HGB: Hemoglobin, AST: Glutamic pyruvic transaminase, ALT: Glutamic pyruvic aminotransferase, HDL-C: High density lipoprotein cholesterol, non-HDL-C: non-High density lipoprotein cholesterol, TC: total cholesterol, FBS: Fasting blood sugar, EDLV: End diastolic diameter of left ventricle, EF: Ejection fraction, HFrEF: Heart failure with reduced ejection fraction, LM: The left main coronary artery, LAD: Left anterior descending branch, LCX: Left circumflex branch, RCA: Right coronary artery, R-HR: Rest heart rate, E-HR: Exercise Heart Rate, E-VE: Exercise Minute ventilation, ΔVE: Margin of Minute ventilation, VE/MVV%: The ratio of minute ventilation to the maximum expected value, VO₂ at VT: Oxygen consumption per kilogram of weight per minute at anaerobic threshold, E-VCO₂: Exercise Carbon dioxide production, ΔVCO₂: Margin of Minute ventilation Carbon dioxide production, VE/VCO₂ slope: Minute ventilation/Carbon dioxide production, R-PĒTCO₂: Rest Partial pressure of end-tidal carbon dioxide, P̄ETCO₂ at VT: Partial pressure of end-tidal carbon dioxide at anaerobic threshold, ΔP̄ETCO₂: Margin of Partial pressure of end-tidal carbon dioxide, MACE: major cardiac events, IQR: Interquartile range.
|                           | Non-MACE (n = 72) | MACE (n = 6) | P     |
|---------------------------|-------------------|--------------|-------|
| E-VE (L/min), median (IQR)| 28.95(25.45,34.00) | 30.95(22.88,35.42) | 0.913 |
| △VE (L/min), median (IQR) | 16.80(13.73,21.20) | 15.20(10.93,21.88) | 0.586 |
| VE/MVV (%), median (IQR)  | 28(25.25,31.75)   | 29.5(20.5,36.25)  | 0.992 |
| VO₂ at VT (ml/kg/min), median (IQR) | 9(10,11) | 9(7.5,11) | 0.135 |
| E-VCO₂ (L/min), median (IQR) | 0.70(0.61,0.85) | 0.64(0.47,0.82) | 0.383 |
| △CO₂ (L/min), median (IQR)  | 0.49(0.38,0.57)  | 0.39(0.25,0.56)  | 0.175 |
| VE/VCO₂ slope, median (IQR)| 35.10(32.53,38.89) | 36.34(35.98,42.86) | 0.181 |
| R-P<sub>ET</sub>CO₂ (mm Hg), median (IQR) | 29(28,30) | 28(26.25,30.25) | 0.254 |
| P<sub>ET</sub>CO₂ at VT (mm Hg), median (IQR) | 33(32,34) | 32(29,33) | 0.016 |
| △P<sub>ET</sub>CO₂ (mm Hg), median (IQR) | 4(3,5) | 3(1.25,4.25) | 0.107 |

WBC: White blood cell, HGB: Hemoglobin, AST: Glutamic pyruvic transaminase, ALT: Glutamic pyruvic aminotransferase, HDL-C: High density lipoprotein cholesterol, non-HDL-C: non-High density lipoprotein cholesterol, TC: total cholesterol, FBS: Fasting blood sugar, EDLV: End diastolic diameter of left ventricle, EF: Ejection fraction, HFrEF: Heart failure with reduced ejection fraction, LM: The left main coronary artery, LAD: Left anterior descending branch, LCX: Left circumflex branch, RCA: Right coronary artery, R-HR: Rest heart rate, E-HR: Exercise Heart Rate, E-VE: Exercise Minute ventilation, △VE: Margin of Minute ventilation, VE/MVV%: The ratio of minute ventilation to the maximum expected value, VO₂ at VT: Oxygen consumption per kilogram of weight per minute at anaerobic threshold, E-VCO₂: Exercise Carbon dioxide production, △VCO₂: Margin of Carbon dioxide production, VE/VCO₂ slope: Minute ventilation/Carbon dioxide production, R-P<sub>ET</sub>CO₂: Rest Partial pressure of end-tidal carbon dioxide, P<sub>ET</sub>CO₂ at VT: Partial pressure of end-tidal carbon dioxide at anaerobic threshold, △P<sub>ET</sub>CO₂: Margin of Partial pressure of end-tidal carbon dioxide, MACE: major cardiac events, IQR: Interquartile range.

Compared with non-MACE group, more patients in MACE group were diabetic (P = 0.035), had higher serum potassium (P = 0.043), higher incidence of heart failure re-hospitalization (P < 0.001) and myocardial infarction (P = 0.005), and lower P<sub>ET</sub>CO₂ at VT (P = 0.016). P<sub>ET</sub>CO₂ at VT was found to have predictive value for re-hospitalization. The area under the curve was 0.789 and the cut-off point was 33.5 mmHg (Fig. 3). P<sub>ET</sub>CO₂ at VT was an independent risk factor for re-hospitalization (OR = 0.635, 95% CI: 0.463–0.871, P = 0.005), as shown in Table 8. The incidence of re-hospitalization was significantly lower when the P<sub>ET</sub>CO₂ at VT was higher than 33.5 mmHg (P = 0.03) (Fig. 4).
Table 8
Analysis of risk factors of MACE in patients with rehabilitation (Cox multivariate regression analysis)

|                          | OR   | 95% CI          | P    |
|--------------------------|------|-----------------|------|
| \( P_{ET}CO_2 \) at VT (mmHg) | 0.635| 0.463–0.871     | 0.005|
| Blood potassium (mmol/l) | 1.239| 0.246–6.249     | 0.795|
| History of diabetes (%)  | 5.871| 0.778–44.282    | 0.086|
| \( P_{ET}CO_2 \) at VT: Partial pressure of end-tidal carbon dioxide at anaerobic threshold.

Discussion

The present study is the first retrospective study evaluating early CR in patients with heart failure after AMI following PCI. The main findings of this study suggest that early CR was able to reduce cardiogenic death in patients with HFrEF, and reduce re-hospitalization in patients with HFmrEF after AMI. Furthermore, the intervention was safe; \( P_{ET}CO_2 \) at VT was an independent risk factor for re-hospitalization.

In patients with HF, research suggested that exercise-based CR could improve QoL, decrease all-cause hospital admissions and HF-dependent hospital admissions in the short term (up to 12 months) and potentially reduce mortality in the long term when compared to no exercise patients \([16, 17]\). Our study expands the previous research by showing that early rehabilitation program involving supervised regular exercise and electrical stimulation can reduce the incidence of cardiac death in patients with HFrEF, and heart failure re-hospitalization in patients with HFmrEF. Elevated serum potassium level and CR ratio were independent risk factors for cardiac death in HFrEF patients after AMI. Moreover, our study suggests that sex, age, history of stroke, and elevated serum potassium were independent risk factors for re-hospitalization in patients with HFmrEF after AMI. Thomsen et.al also reported that hyperkalemia was strongly associated with the degree of renal dysfunction and severe clinical outcomes as well as death in HF patients \([18]\). Houchen et.al found that a 6-week early rehabilitation program including exercise and self-management education, improved short-term exercise tolerance and depression \([7]\). However, the sample size was small in this study and there was no control group for comparison. With a larger study population and a non-CR control group, our results suggest that early CR was not only effective but also safe in patients with CHF soon after AMI.

Exercise intolerance is a major feature of CHF, and is associated with impaired QoL, reduced functional capacity and poor prognosis. In addition to reduced cardiac function, other causes such as reduced pulmonary reserve, impaired skeletal muscle function, etc can diversely and significantly contribute to the syndrome in CHF patients, and even turn into the dominant mechanisms of exercise intolerance \([19]\). Exercise can provide numerous benefits for CHF patients including decreased long-term morbidity and mortality \([20]\), improved cardiac remodeling \([21]\), increased neurovascular functional competency \([22]\), reduced re-hospitalization and improved of cardiorespiratory capacity and QoL \([1, 23]\). The benefits of electrical stimulation included improving blood supply and muscle strength, as well as exercise tolerance in severe CHF patients \([24, 25]\), so it could be offered as an alternative to bicycle training as part of a home-based rehabilitation program \([10]\). In our study, the re-hospitalization in patients
who accepted the 2-week CR after PCI was only related to CRF, but not to serum potassium level or history of diabetes. The reason may be related to the protective effects of exercise on renal function and the improvement of glycolipid metabolism. Our previous research suggested that upregulation of nitric oxide synthases in the kidney and left ventricle may contribute, in part, to the renal and cardiac protective effects of exercise training in cardio renal syndrome in chronic heart failure rats [26]. Furthermore, exercise can reduce early diabetic nephropathy by upregulating nitric oxide synthases as well as ameliorating NADPH oxidase and α-oxoaldehydes in the kidneys of ZDF rats [27].

CRF is now being considered as an essential variable and should be assessed in health screenings [28]. The clinical values of CRF assessment include diagnosis, functional evaluation and prognosis prediction. CPX is the most precise tool to determine exercise tolerance and considered as the reference clinical procedure for assessing CRF by quantifying peak VO\(_2\) which represents an individuals’ capacity to generate energy for strenuous exercise [28]. CHF is a systemic syndrome with the reduction of functional reserve being the outstanding characteristic. The cardiovascular impairment has a direct negative effect on other systems and organs, including the respiratory, renal and neuromuscular systems. CPX is defined as “gold standard” for the CRF of patients with cardiovascular disease, the clinical diagnosis assessment and prognosis prediction can be achieved from direct measurement of VO\(_2\), VCO\(_2\) and VE [29]. The characteristic of CPX data in patients with CHF are: decreased VO\(_2\) at VT < 40% of the predicted VO\(_2\)max, O\(_2\) pulse < 85% and as a plateau, increased VE/VCO\(_2\), wide breathing reserve and usually normal O\(_2\) saturation [29,30]. Weber et al. first published a classification for peak VO\(_2\) results: class A, VO\(_2\) > 20 ml/kg/min; class B, VO\(_2\)16-20 ml/kg/min; class C, VO\(_2\)10-15 ml/kg/min; and class D, VO\(_2\) < 10 ml/kg/min [31]. Arena et al. further proposed the classification based on ventilation/carbon dioxide production relationship (VE/VCO\(_2\) slope) values: class I, VE/VCO\(_2\) slope ≤ 29.9; class II, VE/VCO\(_2\) slope 30-35.9; class III, VE/VCO\(_2\) slope 36-44.9; class IV, VE/VCO\(_2\) slope ≥ 45 [32]. Ferreira et al. noted that the cutoff point of VE/CO\(_2\) slope ≥ 43 would be an appropriate hallmark for heart transplantation determination [33]. Chua et al. found that CHF patients with VE/VCO\(_2\) slope > 34 were at very high risk for death and re-hospitalization [34]. The 2012 EACPR/AHA scientific statement endorsed that peak VO\(_2\) and VE/VCO\(_2\) slope are the most studied CRF variables in CHF patients and both indicated significantly independent prognostic value [11]. For patients under medical treatment, a peak VO\(_2\) < 10.0 ml/kg/min and a VE/VCO\(_2\) slope ≥ 45 exist at the same time would indicate a very poor prognosis over the following 4-year [11]. It should be noted that, in order to achieve the prediction accuracy of peak VO\(_2\) value on CHF, maximal exercise (at least RER > 1.05) should be achieved during the test [29]. Others evaluating the long term prognosis by VE/VCO\(_2\) slope in CHF, and reported that it was an excellent independent value, even better than peak VO\(_2\), and could be achieved only from sub-maximal exercise [35,36]. Similarly our results indicated that CR patients with VE/VCO\(_2\) slope < 36 had a good cardiovascular prognosis.

However, it is difficult to achieve a maximal test in most CHF patients due to the exercise intolerance. The 2016 EACPR/AHA updated the scientific statement, and felt that it is important to note that VO\(_2\) at VT holds broad applicability in the context of assessing the capacity [37]. The VO\(_2\) at VT has also been indicated as a hallmark for the prognosis prediction prior to surgery [38,39]. Furthermore, we also showed that VO\(_2\) at VT is a significant prognostic marker for AMI patients in whom a VO\(_2\) at VT < 10.5 ml/kg/min indicated a poor long term prognosis [40]. The P\(_{ET}\)CO\(_2\) both at rest and in exercise have been found to be positively correlated with the prognosis of systolic heart failure [41]. Abnormalities in the VE/VCO\(_2\) slope and P\(_{ET}\)CO\(_2\) in patients with HCM have been thought
to enhance pulmonary pressures\cite{31, 41}. In the present study, we noted that $P_{ET}CO_2$ at VT was also a predictor of re-hospitalization for patients with CHF after AMI, previous study showed that a lower $P_{ET}CO_2$ was associated with a poor prognosis\cite{40}.

Our previous study demonstrated that $VO_2$ at VT was an independent risk factor for cardiovascular disease prognosis and could be used as an evaluating hallmark for Phase I cardiac rehabilitation in patients with STEMI after PCI\cite{40}. However, the $P_{ET}CO_2$ at VT is an independent risk factor for re-hospitalization in patients with heart failure after AMI. The reasons of the difference may be as follows: first, patients with STEMI after PCI may not have reduced ejection fraction and severe pulmonary dysfunction after PCI operation, a smaller amount of $P_{ET}CO_2$ is an indicator of less CO$_2$ production in the body and/or pulmonary arterial perfusion, or in other words, the cardiac output\cite{42}. The difference in $P_{ET}CO_2$ might be attribute to the difference in infarct location. $VO_2$ at VT is determined not only by the degree of the infarct area but also the peripheral oxygen utilization efficiency, and could be an independent risk factor for the prognosis in patients with STEMI after PCI. Second, ventilation is regulated by the sensitivity of respiratory chemo-receptors and the ergo reflex in skeletal muscles. The sensitivity of respiratory chemo-receptors increases when the sympathetic nerve is activated and/or acidosis occurs. These conditions often occur in HF patients\cite{43}. These subjects experience shortness of breath throughout mild to vigorous activity. While in insufficiently expansion and with increased dead space between artery and alveolus, diffusion of CO$_2$ is less, hence, $P_{ET}CO_2$ decreases. The re-hospitalization associated with exercise intolerance in patients with CHF are multifactorial, including impaired cardiac and pulmonary reserve, and decreased respiratory and peripheral skeletal muscle function, all of them can diversely and significantly contribute to the decrease in $P_{ET}CO_2$. The combined aerobic/resistance/inspiratory training in patients with CHF has been shown to produce positive changes in left ventricular structure and function, which provided additional benefits in both peripheral and diaphragmatic muscle function, dyspnea, cardiopulmonary exercise parameters and QoL\cite{44}.

The limitations of this study include: 1) this is a retrospective study in which patients were not randomly assigned to CR or non-CR group, thus selective bias cannot be avoided; 2) patients in the non-CR group were not assessed for CRF using CPX before discharge; 3) the number of MACE in the early CR group was relatively small. Therefore, further research is needed to confirm the influence of CPF parameters on prognosis prediction and the accuracy of cut-off point value.

**Conclusions**

In conclusion, an early CR decreased the incidence of cardiovascular events in patients with CHF after AMI following PCI. Elevated serum potassium and CR ratio were independent risk factors for MACE in patients not only with HFrEF but also with HFmrEF after AMI. The $P_{ET}CO_2$ at VT was an independent risk factor for re-hospitalization, and could be used as a key evaluating hallmark for early CR in patients with CHF after AMI.

**List Of Abbreviations**

AMI: acute myocardial infarction

CHF: congestive heart failure

CR: cardiac rehabilitation
PCI: percutaneous coronary intervention
HFrEF: heart failure with reduced ejection fraction
HFmrEF: heart failure with mid-range ejection fraction
MACE: major adverse cardiovascular events
CPX: cardio-pulmonary exercise testing
CRF: cardio-respiratory fitness
QoL: quality of life
VO$_2$: oxygen consumption
VCO$_2$: carbon dioxide production
VE: minute ventilation
P$_{ET}$CO$_2$: partial pressure of end-tidal carbon dioxide
RER: respiratory exchange ratio
ROC: receiver operating characteristic
WBC: white blood cell
Cr: creatinine
AST: glutamic pyruvic transaminase
ALT: glutamic pyruvic aminotransferase
TC: total cholesterol
HDL-C: high-density lipoprotein cholesterol
non-HDL-C: non high-density lipoprotein cholesterol
FBG: fasting blood glucose
HGB: hemoglobin
EDLV: End diastolic diameter of left ventricle
EF: Ejection fraction

Declarations
Ethics approval and consent to participate
This work was approved by Medical Ethics Committee of The First Hospital of Jilin University (approval Number: 2016-281) and was exempted from the requirement for informed consent. All information used for data analysis in this study was anonymized.

**Consent for publication**

Not applicable.

**Availability of data and materials**

The data used to support the findings of this study are available from the corresponding author upon request.

**Competing interests**

The authors declare that they have no competing interests, and all authors should confirm its accuracy.

**Funding**

This assessment is funded by National Key R&D Program of China·NO. 2016YFC0900903, and National Natural Science Foundation of China: NO.81301667(3A413X793428). The funding bodies were not involved in the study design, data collection or analysis, or writing of the manuscript.

**Authors' contributions**

P.C. and Y.Z. conceived and designed the study. H.C., Z.L., X.Z., R.L., W.S., L.W. and L.Z. performed the experiments and statistical analysis. H.C. wrote the paper. P.C. and Y.Z. reviewed and edited the manuscript. All authors read and approved the manuscript.

**Acknowledgements**

We thank all the researchers who participated in this work and the funding bodies that sponsored this study.

**References**

1. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013. 62(16): e147-239.

2. Smith SC Jr, Dove JT, Jacobs AK, et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)—executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol. 2001. 37(8): 2215-39.
3. Piña IL, Apstein CS, Balady GJ, et al. Exercise and heart failure: A statement from the American Heart Association Committee on exercise, rehabilitation, and prevention. Circulation. 2003. 107(8): 1210-25.

4. Haykowsky MJ, Tomczak CR, Scott JM, Paterson DI, Kitzman DW. Determinants of exercise intolerance in patients with heart failure and reduced or preserved ejection fraction. J Appl Physiol (1985). 2015. 119(6): 739-44.

5. Rees K, Taylor RS, Singh S, Coats AJ, Ebrahim S. Exercise based rehabilitation for heart failure. Cochrane Database Syst Rev. 2004. (3): CD003331.

6. Piepoli MF, Davos C, Francis DP, Coats AJ, ExTraMATCH Collaborative. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ. 2004. 328(7433): 189.

7. Houchen L, Watt A, Boyce S, Singh S. A pilot study to explore the effectiveness of "early" rehabilitation after a hospital admission for chronic heart failure. Physiother Theory Pract. 2012. 28(5): 355-8.

8. Ponikowski P, Voors AA, Anker SD, et al. [2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure]. Kardiol Pol. 2016. 74(10): 1037-1147.

9. Støylen A, Conraads V, Halle M, Linke A, Prescott E, Ellingsen Ø. Controlled study of myocardial recovery after interval training in heart failure: SMARTEX-HF—rationale and design. Eur J Prev Cardiol. 2012. 19(4): 813-21.

10. Harris S, LeMaitre JP, Mackenzie G, Fox KA, Denvir MA. A randomised study of home-based electrical stimulation of the legs and conventional bicycle exercise training for patients with chronic heart failure. Eur Heart J. 2003. 24(9): 871-8.

11. Guazzi M, Adams V, Conraads V, et al. EACPR/AHA Scientific Statement. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Circulation. 2012. 126(18): 2261-74.

12. Arena R, Myers J, Guazzi M. The future of aerobic exercise testing in clinical practice: is it the ultimate vital sign. Future Cardiol. 2010. 6(3): 325-42.

13. Lauer M, Froelicher ES, Williams M, Kligfield P, American Heart Association Council on Clinical Cardiology, Subcommittee on Exercise, Cardiac Rehabilitation aP. Exercise testing in asymptomatic adults: a statement for professionals from the American Heart Association Council on Clinical Cardiology, Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation. 2005. 112(5): 771-6.

14. Balady GJ, Arena R, Sietsema K, et al. Clinician's Guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. Circulation. 2010. 122(2): 191-225.

15. Kaminsky LA, Arena R, Myers J. Reference Standards for Cardiorespiratory Fitness Measured With Cardiopulmonary Exercise Testing: Data From the Fitness Registry and the Importance of Exercise National Database. Mayo Clin Proc. 2015. 90(11): 1515-23.

16. Taylor RS, Sagar VA, Davies EJ, et al. Exercise-based rehabilitation for heart failure. Cochrane Database Syst Rev. 2014. (4): CD003331.

17. Long L, Mordi IR, Bridges C, et al. Exercise-based cardiac rehabilitation for adults with heart failure. Cochrane Database Syst Rev. 2019. 1: CD003331.

18. Thomsen RW, Nicolaisen SK, Hasvold P, et al. Elevated Potassium Levels in Patients With Congestive Heart Failure: Occurrence, Risk Factors, and Clinical Outcomes: A Danish Population-Based Cohort Study. J Am Heart Assoc. 2018. 7(11).

19. Del Buono MG, Arena R, Borlaug BA, et al. Exercise Intolerance in Patients With Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019. 73(17): 2209-2225.
20. Smart N, Marwick TH. Exercise training for patients with heart failure: a systematic review of factors that improve mortality and morbidity. Am J Med. 2004. 116(10): 693-706.

21. Haykowsky MJ, Liang Y, Pechter D, Jones LW, McAlister FA, Clark AM. A meta-analysis of the effect of exercise training on left ventricular remodeling in heart failure patients: the benefit depends on the type of training performed. J Am Coll Cardiol. 2007. 49(24): 2329-36.

22. Antunes-Correa LM, Kanamura BY, Melo RC, et al. Exercise training improves neurovascular control and functional capacity in heart failure patients regardless of age. Eur J Prev Cardiol. 2012. 19(4): 822-9.

23. Davies EJ, Moxham T, Rees K, et al. Exercise training for systolic heart failure: Cochrane systematic review and meta-analysis. Eur J Heart Fail. 2010. 12(7): 706-15.

24. Dobsák P, Nováková M, Siegelová J, et al. Low-frequency electrical stimulation increases muscle strength and improves blood supply in patients with chronic heart failure. Circ J. 2006. 70(1): 75-82.

25. Karavidas A, Parissis JT, Matzaraki V, et al. Functional electrical stimulation is more effective in severe symptomatic heart failure patients and improves their adherence to rehabilitation programs. J Card Fail. 2010. 16(3): 244-9.

26. Ito D, Ito O, Mori N, et al. Exercise training upregulates nitric oxide synthases in the kidney of rats with chronic heart failure. Clin Exp Pharmacol Physiol. 2013. 40(9): 617-25.

27. Ito D, Cao P, Kakihana T, et al. Chronic Running Exercise Alleviates Early Progression of Nephropathy with Upregulation of Nitric Oxide Synthases and Suppression of Glycation in Zucker Diabetic Rats. PLoS One. 2015. 10(9): e0138037.

28. Kaminsky LA, Arena R, Ellingsen Ø, et al. Cardiorespiratory fitness and cardiovascular disease - The past, present, and future. Prog Cardiovasc Dis. 2019. 62(2): 86-93.

29. Herdy AH, Ritt LE, Stein R, et al. Cardiopulmonary Exercise Test: Background, Applicability and Interpretation. Arq Bras Cardiol. 2016. 107(5): 467-481.

30. Herdy AH, Uhlendorf D. Reference values for cardiopulmonary exercise testing for sedentary and active men and women. Arq Bras Cardiol. 2011. 96(1): 54-9.

31. Weber KT, Kinasewitz GT, Janicki JS, Fishman AP. Oxygen utilization and ventilation during exercise in patients with chronic cardiac failure. Circulation. 1982. 65(6): 1213-23.

32. Arena R, Myers J, Abella J, et al. Development of a ventilatory classification system in patients with heart failure. Circulation. 2007. 115(18): 2410-7.

33. Ferreira AM, Tabet JY, Frankeninstein L, et al. Ventilatory efficiency and the selection of patients for heart transplantation. Circ Heart Fail. 2010. 3(3): 378-86.

34. Chua TP, Ponikowski P, Harrington D, et al. Clinical correlates and prognostic significance of the ventilatory response to exercise in chronic heart failure. J Am Coll Cardiol. 1997. 29(7): 1585-90.

35. Francis DP, Shamim W, Davies LC, et al. Cardiopulmonary exercise testing for prognosis in chronic heart failure: continuous and independent prognostic value from VE/VCO₂ slope and peak VO₂. Eur Heart J. 2000. 21(2): 154-61.

36. Corrà U, Mezzani A, Bosimini E, Scappellato F, Imparato A, Giannuzzi P. Ventilatory response to exercise improves risk stratification in patients with chronic heart failure and intermediate functional capacity. Am Heart J. 2002. 143(3): 418-26.
37. Guazzi M, Arena R, Halle M, Piepoli MF, Myers J, Lavie CJ. 2016 Focused Update: Clinical Recommendations for Cardiopulmonary Exercise Testing Data Assessment in Specific Patient Populations. Circulation. 2016. 133(24): e694-711.

38. Hennis PJ, Meale PM, Grocott MP. Cardiopulmonary exercise testing for the evaluation of perioperative risk in non-cardiopulmonary surgery. Postgrad Med J. 2011. 87(1030): 550-7.

39. Smith TB, Stonell C, Purkayastha S, Paraskevas P. Cardiopulmonary exercise testing as a risk assessment method in non cardio-pulmonary surgery: a systematic review. Anaesthesia. 2009. 64(8): 883-93.

40. Cai H, Zheng Y, Liu Z, et al. Effect of pre-discharge cardiopulmonary fitness on outcomes in patients with ST-elevation myocardial infarction after percutaneous coronary intervention. BMC Cardiovasc Disord. 2019. 19(1): 210.

41. Task Force of the Italian Working Group on Cardiac Rehabilitation Prevention, Working Group on Cardiac Rehabilitation and Exercise Physiology of the European Society of Cardiology, Piepoli MF, et al. Statement on cardiopulmonary exercise testing in chronic heart failure due to left ventricular dysfunction: recommendations for performance and interpretation. Part I: definition of cardiopulmonary exercise testing parameters for appropriate use in chronic heart failure. Eur J Cardiovasc Prev Rehabil. 2006. 13(2): 150-64.

42. Arena R, Myers J, Abella J, et al. Defining the optimal prognostic window for cardiopulmonary exercise testing in patients with heart failure. Circ Heart Fail. 2010. 3(3): 405-11.

43. Adachi H. Cardiopulmonary Exercise Test. Int Heart J. 2017. 58(5): 654-665.

44. Laoutaris ID, Adamopoulos S, Manginas A, et al. Benefits of combined aerobic/resistance/inspiratory training in patients with chronic heart failure. A complete exercise model? A prospective randomised study. Int J Cardiol. 2013. 167(5): 1967-72.

Figures
Figure 1

The Kaplan-Mayer curves of MACE-free survival in the HFrEF group. CR: cardiac rehabilitation, NCR: non cardiac rehabilitation, MACE: major cardiac events.
Figure 2

The Kaplan-Mayer curves of MACE-free survival in the HFmrEF group. CR: cardiac rehabilitation, NCR: non cardiac rehabilitation, MACE: major cardiac events.
Figure 3

The ROC curve of PETCO2 at VT. PETCO2 at VT: Partial pressure of end-tidal carbon dioxide at anaerobic threshold.
Figure 4

The Kaplan-Mayer curves of MACE-free survival in patients with rehabilitation. PETCO2 at VT: Partial pressure of end-tidal carbon dioxide at anaerobic threshold; MACE: major cardiac events.